Gene Logic Collaboration Reveals Genomic Predictors of Parkinson's Disease

  
    
  
  
    
      Gene Logic Inc. (NASDAQ:GLGC) announced today that a collaborative study 
      between its Genomics Division and Mayo Clinic has found biomarkers that 
      predict susceptibility to Parkinson’s disease 
      and age of disease onset. The study was novel in its detailed and 
      comprehensive analysis of genes and their polymorphic variants across a 
      specific biologic pathway. This work may also provide a model for the 
      study of other complex diseases such as Alzheimer’s.
    
    
      Parkinson’s disease is a chronic and 
      progressive movement disorder that affects nearly one million Americans. 
      The collaborators used sophisticated bioinformatic analysis methods to 
      compare gene sequence variations called single nucleotide polymorphisms 
      (SNPs) in the genomes of Parkinson’s disease 
      patients to those of their disease-free siblings. The collaborators 
      targeted variants of genes related to the axon guidance pathway, a 
      neural development pathway that plays an important role in the wiring of 
      the brain during fetal development.
    
    
      Gene Logic provided gene expression data analysis and data 
      interpretation, comparing the whole-genome study data to the company’s 
      Parkinson’s disease gene expression 
      knowledgebase, referred to in the study as the most comprehensive such 
      database to date. Jarlath ffrench-Mullen, Ph.D., Gene Logic Scientific 
      Director, Central Nervous System, and a co-author of the study said, “The 
      study methodology opens doors to more in-depth genetic understanding of 
      complex diseases, demonstrating the value of our clinical and genomics 
      assets and capabilities. Gene expression profiles are used in such 
      studies to identify, understand and confirm the dysregulation of 
      specific genes and gene variants in a target pathway. This study 
      augments our intellectual property position around a growing set of 
      useful markers for Parkinson’s disease and 
      other complex diseases, affording excellent opportunities to develop 
      diagnostic, prognostic, or therapeutic products.”
    
    
      Gene Logic Overview
    
    
      Gene Logic is transforming into a biopharmaceutical development company 
      through partnerships with pharmaceutical companies. Our partners provide 
      Gene Logic with access to their drug candidates that have been assessed 
      as safe in human clinical trials but discontinued for other reasons. 
      Gene Logic applies its drug indication platform to find new therapeutic 
      uses for the drug candidates. Gene Logic expects to receive milestone 
      payments and royalties on drug candidates that our partners choose to 
      develop based on the indications we find or, if the partner elects not 
      to pursue such new indications, Gene Logic may receive ownership and 
      development rights.
    
    
      Gene Logic has also developed proprietary genomics databases and 
      services to enable customers worldwide to discover and prioritize drug 
      targets, identify biomarkers, predict toxicity and understand mechanisms 
      of toxicity, and obtain insights into the efficacy of specific compounds.
    
    
      Founded in 1994, Gene Logic is headquartered in Gaithersburg, Maryland, 
      with additional research and development facilities in Cambridge, 
      Massachusetts. The Company currently has about 150 employees worldwide. 
      For more information, visit www.genelogic.com 
      or call toll-free – 1/800/GENELOGIC.
    
    
      Safe Harbor Statement
    
    
      This press release contains “forward-looking 
      statements,” as such term is used in the 
      Securities Exchange Act of 1934, as amended. Such forward-looking 
      statements include the Company’s ability to 
      identify strategies for making its businesses successful and the impact 
      of such strategies on our business and financial performance and on 
      shareholder value. Forward-looking statements typically include the 
      words “expect,” “anticipate,” 
      “believe,” “estimate,” 
      “intend,” “may,” 
      “will,” and 
      similar expressions as they relate to Gene Logic or its management. 
      Forward-looking statements are based on our current expectations and 
      assumptions, which are subject to risks and uncertainties. They are not 
      guarantees of our future performance or results. Our actual performance 
      and results could differ materially from what we project in 
      forward-looking statements for a variety of reasons and circumstances, 
      including particularly such risks and uncertainties that may affect the 
      Company’s operations, financial condition and 
      financial results and that are discussed in detail in the Company’s 
      Annual Report on Form 10-K and our other subsequent filings with the 
      Securities and Exchange Commission. They include, but are not limited 
      to: whether we will be able to identify and successfully implement 
      strategies, on favorable terms or at all, for improving the performance 
      and value of our businesses and improving the value of our Genomics 
      business and whether repositioned compounds are successfully returned to 
      our customers’ pipelines and generate sales, 
      and resulting milestones and royalties for the Company or whether we 
      acquire repositioned compounds on acceptable terms and are able to 
      derive revenue from these compounds through licensing or otherwise, 
      whether we can enter into agreements to develop sufficient compounds to 
      fulfill our plans for the Drug Repositioning Division, and improving the 
      value of our businesses to shareholders; whether there will be remaining 
      price adjustments or liabilities associated with the sale of the 
      Pre-Clinical Division, whether we will be able successfully to manage 
      our existing cash adequately and whether we will have access to 
      financing on sufficiently favorable terms to maintain our businesses and 
      effect our strategies, including development of repositioned compounds; 
      whether we will be able to recruit and retain qualified personnel, 
      particularly in light of our restructuring efforts; potential negative 
      effects on our operations and financial results from workforce 
      reductions, other restructuring activities, and the evaluation of 
      strategic options; the potential loss of significant customers; the 
      possibility of further write-down of the value of certain intangible 
      assets of the Company, including goodwill associated with the Genomics 
      Division; and the possibility of delisting from NASDAQ Global Markets, 
      which could have an adverse effect on the value of our stock. Gene Logic 
      undertakes no obligation to update or revise any forward-looking 
      statements, whether as a result of new information, future events or 
      otherwise.